A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Status:
Not yet recruiting

Trial end date:
2024-07-30

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Phase 2

Janssen Research & Development, LLC

Golimumab